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Abstract
Background: Magnetic resonance arthrography (MRA) requires intra-articular injection of gadolinium-based diluted
paramagnetic contrast material. To our knowledge, gadobenate dimeglumine (Gd-BOPTA) has never been used for
intra-articular applications. Our aim was to test in vitro different concentrations of Gd-BOPTA to be potentially used
to perform MRA.
Methods: Gd-BOPTA was diluted in saline (NaCl 0.9%) to achieve different concentrations (4mmol/l; 2 mmol/l; 1 mmol/l;
0.67mmol/l; 0.5 mmol/l). Six sets of five sterile pipes were prepared with 5ml of each solution, five sets added with 0.5 ml
of fresh synovial fluid. Two separate pipes were prepared with 5ml of gadopentetate dimeglumine (Gd-DTPA) at 2
mmol/l, one pipe added with 0.5ml of synovial fluid. Pipes were imaged using a T1-weighted sequence at 1.5 T. For each
pipe, signal intensity (SI) in arbitrary units (au) was measured.
Results: SI reproducibility range was 86–99%. Mean Gd-BOPTA SI in pipes containing synovial fluid increased from
1236 ± 8au (0.5mmol/l) up to 1610 ± 44au (1mmol/l) and down to 1405 ± 33au (4mmol/l). Mean Gd-BOPTA SI in pipes
without synovial fluid increased from 1184 ± 29au (0.5mmol/l) up to 1530 ± 38au (1mmol/l), and down to 1347 ± 39au
(4mmol/l). SI of pipes without synovial fluid was lower than that of pipes with synovial fluid for both Gd-BOPTA and Gd-
DTPA (P≤ 0.002). Regarding pipes with synovial fluid, mean Gd-DTPA SI at 2mmol/l was 1246 ± 27au. Compared with
Gd-BOPTA, SI was not different at 0.5mmol/l (− 0.2%, P = 0.587) while it was higher (P < 0.001) at all other concentrations
(range + 13.3%[4mmol/l] − + 28.3%[1mmol/l]). Regarding pipes without synovial fluid, mean Gd-DTPA SI at 2mmol/l was
1275 ± 56au. Compared with Gd-BOPTA, SI was lower at 0.5mmol/l (− 6.8%,P < 0.001), while it was higher (P < 0.001) at all
other concentrations (range + 6.1%[4mmol/l]− + 19.6% [1mmol/l]).
Conclusions: In vitro, Gd-BOPTA at 1mmol/ had a + 28% SI increase in comparison to Gd-DTPA 2mmol/l. SI similar to
Gd-DTPA can be obtained using one fourth concentration of Gd-BOPTA.
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Background
Magnetic resonance imaging (MRI) has become the
most important diagnostic tool for the assessment of
joint disorders throughout the body, allowing for detect-
ing abnormalities of the joint space, cartilage, fibrocarti-
lages, tendons, ligaments, and synovial tissue [1]. In this
setting, a further advanced tool is represented by MR
arthrography (MRA), which is mainly used to evaluate
young and less young patients and has been demon-
strated to be superior in detecting a number of intra-
articular joint abnormalities compared to conventional
MRI [2, 3].
MRA requires intra-articular injection of gadolinium-based
diluted paramagnetic contrast material [1, 4]. Contrast solu-
tion is injected until the capsule distends [5]. Traditionally,
paramagnetic contrast solution was prepared manually, dilut-
ing a certain amount of gadolinium-based contrast agent into
saline solution to obtain an approximate concentration of 2
mmol/l [5]. A recent survey showed this approach is still
used in about 60% of institutions [6]. On the other hand, two
commercial preparations are available as pre-filled syringes
ready to be injected. These solutions are based on gadoteric
acid (Gd-DOTA, 2.5mmol/l; Dotarem, Guerbet, France) or
on gadopentetate dimeglumine (Gd-DTPA, 2mmol/l;
Magnevist, Bayer, Germany). These two contrast agents have
different molecular structures and properties but have similar
R1-relaxivity values of approximately 4.2–5.3 l/mmols− 1 at
1.5 T and produce similar contrast enhancement when ad-
ministered at the same dose [7]. Gadobenate dimeglumine
(Gd-BOPTA, MultiHance, Bracco Imaging SpA, Italy) is a
gadolinium-based contrast agent which has unique features
compared to other agents, including very high R1-relaxivity
thanks to a transient weak binding to blood proteins and is
mostly used for liver imaging [8].
To our knowledge, Gd-BOPTA has never been used
for intra-articular applications.
The purpose of our study was to test in vitro different
concentrations of Gd-BOPTA to be potentially used for
MRA.
Methods
Preparation of pipes
Six sets of six sterile pipes were prepared at different
concentrations, 36 pipes overall (Fig. 1a). For all sets,
Gd-BOPTA and saline solution (NaCl 0.9%) were mixed
into five pipes in order to achieve a concentration of 4
mmol/l, 2 mmol/l, 1 mmol/l, 0.67 mmol/l, and 0.5 mmol/
l; the sixth pipe was filled with 5 ml of 2 mmol/l pre-
diluted Gd-DTPA and served as a reference (Fig. 1b).
We used Gd-DTPA as reference standard since it is one
of the most commonly used contrast agents in pre-
diluted syringes for MRA examinations and it is also that
used at our Institution.
To simulate the environment of a joint, five sets of
pipes prepared as reported above were added with
0.5 ml of fresh synovial fluid withdrawn from the
knees of five patients presenting to our department
for intra-articular injections (three males, two females;
mean age 68 ± 8 years) (Fig. 1c). These patients were
Fig. 1 Six sets of six sterile pipes were prepared at different concentrations, 36 pipes overall (a). For all sets, Gd-BOPTA and saline solution (NaCl
0.9%) were mixed into five pipes in order to achieve a concentration of 4 mmol/l, 2 mmol/l, 1 mmol/l, 0.67 mmol/l, and 0.5 mmol/l; the sixth pipe
was filled with 5 ml of 2 mmol/l pre-diluted Gd-DTPA and served as a reference (b). To simulate the environment of a joint, five sets of pipes
were added with 0.5 ml of fresh synovial fluid withdrawn from the knees of five patients presenting to our department for intra-articular
injections (c)
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all affected by degenerative osteoarthritis grade II ac-
cording to Kellgren-Lawrence [9].
Imaging protocol and statistical analysis
All six sets of pipes were imaged independently using an
axial T1-weighted sequence (TE = 9.8 ms, TR = 678ms,
slice thickness 3.5 mm, FOV 320 × 320mm) at 1.5 T
(Sonata Maestro Class, Siemens Medical Solution, Er-
langen, Germany) using a 4-channel phased-array sur-
face coil. The same sequence was repeated twice to test
reproducibility. Fourteen slices per pipe were obtained.
For each image, signal intensity (SI) in arbitrary units
(au) was measured by one observer using a 4-mm diam-
eter region of interest (Horos 3.3.5, www.horosproject.
info) placed approximately in the middle of the image.
For each pipe, the mean and standard deviation (SD) of
SI over the 14 regions of interest was calculated. To
compare the SI of Gd-BOPTA and Gd-DTPA, data from
all the pipes and all the measurements were averaged.
Reproducibility between SI of each pipe was tested using
the Bland-Altman method. Differences of SI between
pipes at the same concentration of the two sets (with or
without synovial fluid) and between pipes containing Gd-
BOPTA at different concentrations and Gd-DTPA were
assessed using the Mann-Whitney U test. Differences of
SI among the five sets of pipes containing Gd-BOPTA per
each concentration were tested using the Kruskal-Wallis
test. The SPSS program (v.24, IBM, NY) was used. P-value
threshold was set at 0.003 for multiple comparison
correction.
Results
Figure 2 shows T1-weighted axial scan of the two dif-
ferent sets of pipes containing different solutions of
gadolinium-based contrast with and without addition
of synovial fluid.
Reproducibility
The reproducibility of SI measurement on the same pipe
ranged from 86% (Gd-BOPTA 0.67 mmol/l without syn-
ovial fluid) to 99% (Gd-BOPTA 0.5 mmol/l, set #2 and
set #3). Full data is reported in Table 1.
SI of Gd-BOPTA pipes
The mean SI of Gd-BOPTA in pipes containing synovial
fluid increased from 1236 ± 8 au at 0.50mmol/l (set #4,
scan #1) up to 1610 ± 44 au at 1.00mmol/l (set #4, scan #1)
and down to 1405 ± 33 au at 4.00mmol/l (set #5, scan #2).
SI within pipe sets was homogeneous, with no significant
differences among them (P > 0.004).
The mean SI of Gd-BOPTA in pipes not containing
synovial fluid showed an increase from 1184 ± 29 au at
0.50 mmol/l (set #6, scan #1) up to 1530 ± 38 au at 1.00
mmol/l (set #6, scan #1), and down to 1347 ± 39 au at
4.00 mmol/l (set #6, scan #1).
SI of pipes without synovial fluid was significantly
lower than that of pipes with synovial fluid for both Gd-
BOPTA and Gd-DTPA (P ≤ 0.002).
Full data is reported in Table 1 and graphically repre-
sented in Fig. 3.
Comparison between Gd-BOPTA and Gd-DTPA
Regarding pipes with synovial fluid, the mean SI of Gd-
DTPA at 2 mmol/l was 1246 ± 27 au. In comparison
with Gd-BOPTA, SI was not significantly different at
0.5 mmol/l (− 0.2%, P = 0.587) while it was significantly
higher at all other concentrations (range + 13.3% at 4
mmol/l to 28.3% at 1 mmol/l, P < 0.001).
Regarding pipes without synovial fluid, the mean SI
of Gd-DTPA at 2 mmol/l was 1275 ± 56 au. In com-
parison with Gd-BOPTA, SI was significantly lower at
0.5 mmol/l (− 6.8%, P < 0.001) while it was signifi-
cantly higher at all other concentrations (range + 6.1%
at 4 mmol/l to 19.6% at 1 mmol/l, P < 0.001). Full data
is reported in Table 2.
Discussion
Our in vitro experience demonstrated that synovial fluid
slightly but significantly increased SI of Gd-BOPTA. In
pipes containing synovial fluid, Gd-BOPTA at 1 mmol/l
had a + 28% SI increase in comparison to Gd-DTPA 2
mmol/l.
Gd-BOPTA has unique features that distinguish it from
all other gadolinium-based contrast media. In particular, it
has a dual route of elimination from the body that enables
Gd-BOPTA to be used both as nonspecific agent and liver-
specific agent [10]. Moreover, a higher R1-relaxivity com-
pared to other gadolinum-based contrast agents permits
Fig. 2 T1-weighted axial scan of two different sets of pipes
containing different solutions of gadolinium-based contrast (a) with
or (b) without addition of synovial fluid
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lower overall doses to be used or provides increased SI en-
hancement at equivalent dose [7]. In fact, Gd-BOPTA has a
weak and transient interaction with serum albumin which
confers a partial blood-pool effect and a lower rate of con-
trast dilution compared to that of other gadolinium agents
[11]. Indeed, Gd-BOPTA has been proven to be effective in
brain [12], vascular [13], liver [14], and breast MRI [15], in
which it can be used at lower doses compared to other
gadolinium-based agents. At present, however, the use of
Gd-BOPTA has been limited to the liver only, given the re-
ported accumulation of Gd in patients’ tissues after repeated
intravenous administrations [16, 17]. On the other hand, it
should also be noted that a recent report showed how Gd
does not accumulate in patients undergoing MRA [18].
Regarding MRA, the use of Gd-BOPTA has never
been clearly reported before except for an animal study
published in 2007 in which its effect on cartilage was
tested [19]. However, in some studies dealing with MRA
the type of contrast agent may be not reported [20].
Moreover, other studies used Gd-BOPTA to perform in-
direct MRA [21], an alternative imaging technique based
on the premise that contrast material administered intra-
venously diffuses into the joint space, owing to high
vascularization of the synovial membrane and lack of
Table 1 Comparison of signal intensities of different solution concentrations of gadolinium-based contrast agents with or without
addition of synovial fluid and their reproducibility
Gd-BOPTA 0.5
mmol/l
Gd-BOPTA 0.67
mmol/l
Gd-BOPTA 1
mmol/l
Gd-BOPTA 2
mmol/l
Gd-BOPTA 4
mmol/l
Gd-DTPA 2
mmol/l
Saline
0.5 ml of
synovial fluid
Set
#1
Scan #1 1241 ± 19 1481 ± 50 1583 ± 34 1521 ± 29 1414 ± 34 1204 ± 59 403 ±
6
Scan #2 1247 ± 13 1464 ± 60 1577 ± 35 1514 ± 26 1416 ± 37 1234 ± 47 403 ±
6
Coefficient of
repeatability
97% 90% 95% 95% 94% 89% 96%
Set
#2
Scan #1 1241 ± 8 1497 ± 49 1602 ± 52 1534 ± 39 1424 ± 37 1253 ± 50 391 ±
11
Scan #2 1241 ± 7 1461 ± 62 1604 ± 34 1542 ± 32 1419 ± 36 1238 ± 61 398 ±
16
Coefficient of
repeatability
99% 90% 93% 94% 93% 87% 91%
Set
#3
Scan #1 1249 ± 13 1474 ± 45 1608 ± 37 1536 ± 35 1410 ± 32 1253 ± 37 398 ±
9
Scan #2 1244 ± 21 1442 ± 54 1596 ± 34 1527 ± 29 1415 ± 32 1234 ± 40 400 ±
7
Coefficient of
repeatability
99% 90% 93% 94% 93% 87% 91%
Set
#4
Scan #1 1236 ± 8 1486 ± 61 1610 ± 44 1524 ± 32 1406 ± 38 1232 ± 46 409 ±
8
Scan #2 1243 ± 17 1470 ± 46 1584 ± 37 1521 ± 32 1408 ± 28 1239 ± 53 409 ±
7
Coefficient of
repeatability
96% 90% 94% 93% 94% 90% 94%
Set
#5
Scan #1 1246 ± 19 1496 ± 49 1601 ± 38 1540 ± 26 1411 ± 34 1266 ± 55 404 ±
6
Scan #2 1240 ± 14 1484 ± 44 1601 ± 27 1545 ± 27 1405 ± 33 1246 ± 46 403 ±
10
Coefficient of
repeatability
96% 91% 95% 95% 93% 91% 95%
Differences between sets 0.714 0.285 0.213 0.013 0.411 0.165 0.000
No synovial
fluid
Set
#6
Scan #1 1184 ± 29 1441 ± 49 1530 ± 38 1478 ± 39 1347 ± 39 1292 ± 45 401 ±
5
Scan #2 1191 ± 31 1383 ± 58 1520 ± 36 1454 ± 34 1358 ± 35 1257 ± 62 387 ±
10
Coefficient of
repeatability
94% 86% 93% 93% 94% 89% 92%
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basement membrane in its capillaries. Compared with
the direct technique, indirect MR arthrography has the
main disadvantage of not allowing for capsular disten-
sion. On the other side, intravenous injection allows
assessing disease activity in patients affected by inflam-
matory joint diseases [22]. At any rate, the use of direct
MRA is continuously increasing, notwithstanding im-
proved coils at 1.5 T and increased diffusion of 3 T
systems.
Compared to 2 mmol/l solution of Gd-DTPA, SI of
Gd-BOPTA was higher at all concentrations except
0.5 mmol/l. The highest SI was achieved at 1 mmol/l,
while a similar SI was obtained at 0.5 mmol/l in pipe
sets added with synovial fluid. In clinical practice,
these differences may be negligible, implying that also
a low concentration of gadolinium-based solution can
be considered acceptable. The main practical result of
these findings is that, in a simulated joint environ-
ment, the same SI of pre-diluted Gd-DTPA syringes
can be obtained with up one fourth concentration of
Gd-BOPTA. However, in vivo testing of this specula-
tion should be warranted.
We acknowledge the limitations of an in vitro study
in which joint environment has been reproduced only
adding a small amount of synovial fluid to the contrast
agent contained in sterile pipes. This implies that our
data may be not directly applicable in vivo, as other
factors (e.g., synovial tissue, inflammatory cytokines)
may be implicated in the interaction with Gd-BOPTA.
Also, body temperature may somewhat affect behavior
of contrast agents in vivo, while our experiment was
conducted at room temperature. Moreover, we used
Fig. 3 Graphical representation of signal intensity of different solutions of gadolinium-based contrast agents with or without addition of synovial
fluid and saline solution. Signal intensity of pipes without synovial fluid was significantly lower than that of pipes with synovial fluid
Table 2 Comparison of signal intensities of different Gd-BOPTA concentrations to Gd-DTPA 2mmol/l with or without addition of
synovial fluid
Gd-BOPTA 0.5
mmol/l
Gd-BOPTA 0.67
mmol/l
Gd-BOPTA 1
mmol/l
Gd-BOPTA 2
mmol/l
Gd-BOPTA 4
mmol/l
Saline
With synovial
fluid
Gd-DTPA 2
mmol/l
1244 ± 9 1481 ± 41 1598 ± 30 1529 ± 24 1412 ± 23 401 ± 8
1246 ± 27 −0.2% 18.9% 28.3% 22.7% 13.3% −67.8%
P = 0.587 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P <
0.001
Without
synovial fluid
1188 ± 29 1412 ± 60 1525 ± 36 1466 ± 38 1353 ± 37 394 ±
10
1275 ± 56 −6.8% 10.7% 19.6% 15.0% 6.1% −69.1%
P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P <
0.001
Note. - P-values and percentages refer to comparison between the corresponding concentration of Gd-BOPTA and Gd-DTPA
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the synovial fluid withdrawn from the knees of pa-
tients with a mean age of 68 years and mild degenera-
tive osteoarthritis. It is known that synovial fluid of
elderly subjects may contain less glycoproteins and
glycosaminoglycans. Thus, in younger subjects, in
whom MRA is more likely to be performed, results
may be somewhat different. We can speculate that a
higher content of glycoproteins may further improve
SI, although at present we do not have data to confirm
such hypothesis. Finally, we did not assess separately
T1 and T2 effects of the contrast media and our re-
sults are only valid for one specific parameter set TR
and TE. Also, relative signal changes with noise cor-
rection should also be measured to assess reliable
relaxivity values R1 and R2. However, our study was
primarily aimed to measure SI, that is the most useful
parameter that may affect clinical practice.
Conclusions
In conclusion, in vitro, Gd-BOPTA at 1mmol/ had a +
28% SI increase in comparison to Gd-DTPA 2mmol/l. A
SI similar to Gd-DTPA can be obtained using one fourth
concentration of Gd-BOPTA. Further in vivo studies are
warranted to confirm clinical applicability and value of
our results.
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